Artiva Biotherapeutics (ARTV) 2025 Conference September 03, 2025 09:45 AM ET Company ParticipantsJosh Schimmer - Managing DirectorFred Aslan - President, CEO & DirectorJosh SchimmerAll right, I think we're ready to get started. Welcome everyone. I'm Josh Shimmer from the Kanter Biotech Equity Research Team. Very pleased to introduce from Artiva Biotherapeutics, Fred Aslan, Chief Executive Officer, to give us a snapshot of the program. I have a feeling we're going to be talking a lot about CYFLU during the c ...

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30, 2025. "We remain focused on the execution of our clinical trials and continue to believe in the differentiated potential of NK cell therapy to address unmet needs in the treatment of autoimmune diseases," said Paul J. Hastings, CEO of Nkar ...

Core Insights - NKGen Biotech, Inc. is set to present its findings on the mechanism of action for troculeucel, a non-genetically modified NK cell therapy for Alzheimer's disease, at the Alzheimer's Association International Conference 2025 [1][2] - The presentation will include Phase I biomarker data that confirms the therapy's enhanced cytotoxicity in Alzheimer's patients [2][3] - Troculeucel is recognized as SNK01 by the World Health Organization, marking a significant milestone in its development for treating neurodegenerative disorders and various cancers [4] Company Overview - NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, focusing on innovative autologous and allogeneic NK cell therapeutics [5] - The company aims to commercialize its therapies, with troculeucel being a key candidate in its pipeline [4][5]

Core Insights - NKGen Biotech, Inc. is focused on developing innovative NK cell therapeutics, with a presentation at the upcoming Alzheimer's & Parkinson's Drug Development Summit highlighting their autologous NK cell therapy, troculeucel, for neurodegenerative diseases [1][2] Company Overview - NKGen Biotech is a clinical-stage biotechnology company headquartered in Santa Ana, California, specializing in autologous and allogeneic NK cell therapeutics [6] - Troculeucel, the company's novel cell-based immunotherapeutic drug candidate, is being developed for neurodegenerative disorders and various cancers, with its International Nonproprietary Name (INN) assigned as SNK01 by the WHO [5] Presentation Details - Dr. Paul Y. Song will present on March 20, 2025, at 12:00 PM ET, focusing on the potential of enhanced NK cell therapies for neurodegenerative diseases, specifically introducing troculeucel [3] - The presentation will include data from a Phase 1 clinical trial showing early signs of clinical benefit, leading to FDA Fast Track designation for moderate Alzheimer's Disease and a new Investigational New Drug application for Parkinson's Disease [3] Summit Information - The Alzheimer's & Parkinson's Drug Development Summit is the only industry-focused event covering the entire drug development process, featuring over 150 experts discussing advancements in neurodegenerative therapeutics [2]

Core Viewpoint - NKGen Biotech has initiated the administration of troculeucel, an autologous NK cell therapy, to a stroke patient under a compassionate use IND approved by the FDA, marking a significant step in exploring its therapeutic potential in post-stroke treatment [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on developing and commercializing innovative autologous and allogeneic NK cell therapeutics, headquartered in Santa Ana, California [7]. Product Development - Troculeucel is a novel, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate, being developed for neurodegenerative disorders and various cancers. The WHO has assigned the International Nonproprietary Name (INN) "troculeucel" for SNK01, which is a significant milestone for the company [6]. Clinical Collaboration - NKGen is collaborating with Dr. Dimitri Sigounas and Dr. Amarendra K. Neppalli from George Washington University Medical Center to explore the potential of troculeucel in reducing chronic neuroinflammation and damage in stroke patients [3][5]. Clinical Assessment - The stroke patient receiving troculeucel will undergo regular independent assessments by Dr. Sigounas at GWU Medical Center to evaluate the treatment's effectiveness [4]. Research Insights - Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are identified as markers of brain injury, and previous trials have shown that troculeucel can cross the blood-brain barrier to reduce cerebrospinal fluid levels of these markers, indicating its potential to improve outcomes in stroke patients [5].